Mankind Pharma's Rs 511 crore investment in Armed Cell Therapeutics targets next-generation CAR-T therapies for difficult-to-treat cancers.
India pharma news: Mankind Pharma’s ?511 crore ACTx deal, Dr Reddy’s US FDA observations, Aurobindo’s ADQUEY launch and Novo Nordisk’s sickle cell initiative.
Vanda Pharmaceuticals has put its VQW-765 anxiety drug programme on hold after a Phase III trial failed to meet its primary endpoint.
Clinical trial site readiness gains focus as AstraZeneca and NIPER Raebareli partner to strengthen research infrastructure across 25 emerging Indian geographies.
HPV-targeted cancer therapy faces a setback as BioNTech's BNT113 misses its first major clinical trial endpoint in head and neck cancer.
ALK7 RNAi therapy is emerging as a potential alternative approach to obesity treatment as Roche expands its experimental drug pipeline.
Lung health research advances on two fronts as scientists link microbiome changes to lingering Covid symptoms, while IPF drug trials deliver contrasting results.
The most popular schizophrenia pill gets a once-a-month shot as Teva wins FDA approval for its WELTRUZA injection.
NVIDIA-backed AI is powering Iambic Therapeutics’ cancer drug pipeline as the biotech prepares for an IPO targeting a valuation of USD 806 million.
AI is reshaping the full pharma stack, accelerating drug discovery while improving formulation, clinical testing, and delivery.